S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

Equillium Stock Forecast, Price & News

+0.47 (+10.51%)
(As of 12/8/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
57,434 shs
Average Volume
208,793 shs
Market Capitalization
$145.19 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive EQ News and Ratings via Email

Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter.

Equillium logo

About Equillium

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.


Equillium (NASDAQ:EQ) Rating Reiterated by SVB Leerink
December 8, 2021 |  americanbankingnews.com
Equillium's (EQ) Buy Rating Reaffirmed at HC Wainwright
November 15, 2021 |  americanbankingnews.com
Equillium to Present at Two Upcoming Investor Conferences
November 9, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Sales & Book Value

Annual Sales
Book Value
$2.58 per share


Net Income
$-29.81 million
Pretax Margin




Free Float
Market Cap
$145.19 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.20 out of 5 stars

Medical Sector

390th out of 1,394 stocks

Pharmaceutical Preparations Industry

178th out of 674 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Equillium (NASDAQ:EQ) Frequently Asked Questions

Is Equillium a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Equillium stock.
View analyst ratings for Equillium
or view top-rated stocks.

How has Equillium's stock been impacted by Coronavirus?

Equillium's stock was trading at $3.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EQ stock has increased by 41.1% and is now trading at $4.94.
View which stocks have been most impacted by COVID-19

When is Equillium's next earnings date?

Equillium is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Equillium

How were Equillium's earnings last quarter?

Equillium, Inc. (NASDAQ:EQ) issued its earnings results on Wednesday, November, 10th. The company reported ($0.35) EPS for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.01.
View Equillium's earnings history

What price target have analysts set for EQ?

5 brokers have issued twelve-month target prices for Equillium's shares. Their forecasts range from $12.00 to $18.00. On average, they expect Equillium's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 193.5% from the stock's current price.
View analysts' price targets for Equillium
or view top-rated stocks among Wall Street analysts.

Who are Equillium's key executives?

Equillium's management team includes the following people:
  • Bruce D. Steel, President, Chief Executive Officer & Director
  • Christine Zedelmayer, Chief Operating Officer & Senior Vice President
  • Jason A. Keyes, Chief Financial Officer (LinkedIn Profile)
  • Stephen Connelly, Director & Chief Scientific Officer (LinkedIn Profile)
  • Dolca Thomas, Chief Medical Officer, EVP-Research & Development

What is Geoffrey A. Rotstein's approval rating as Equillium's CEO?

7 employees have rated Equillium CEO Geoffrey A. Rotstein on Glassdoor.com. Geoffrey A. Rotstein has an approval rating of 50% among Equillium's employees. This puts Geoffrey A. Rotstein in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When did Equillium IPO?

(EQ) raised $70 million in an initial public offering on Friday, October 12th 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO.

What is Equillium's stock symbol?

Equillium trades on the NASDAQ under the ticker symbol "EQ."

Who are Equillium's major shareholders?

Equillium's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (10.79%), Geode Capital Management LLC (0.52%), Two Sigma Securities LLC (0.29%), Citadel Advisors LLC (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Equillium stock include Jason A Keyes, Jason A Keyes and Stephen Connelly.
View institutional ownership trends for Equillium

Which major investors are buying Equillium stock?

EQ stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Two Sigma Securities LLC, Citadel Advisors LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Equillium
or or view top insider-buying stocks.

How do I buy shares of Equillium?

Shares of EQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Equillium's stock price today?

One share of EQ stock can currently be purchased for approximately $4.94.

How much money does Equillium make?

Equillium has a market capitalization of $145.19 million. The company earns $-29.81 million in net income (profit) each year or ($1.35) on an earnings per share basis.

How many employees does Equillium have?

Equillium employs 31 workers across the globe.

What is Equillium's official website?

The official website for Equillium is equilliumbio.com.

Where are Equillium's headquarters?

How can I contact Equillium?

Equillium's mailing address is 2223 AVENIDA DE LA PLAYA SUITE 108, LA JOLLA CA, 92037. The company can be reached via phone at (858) 412-5302 or via email at [email protected].

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.